drugset / Trial / NCT07580586
A Single Centre, Open-label, 2-period Fixed-sequence, Phase I Clinical Study to Evaluate the Effect of BV100 on the Pharmacokinetics of Polymyxin B in Healthy Volunteers
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is an open-label, fixed sequence Phase I clinical study to evaluate the effect of multiple doses of BV100 on the PK of polymyxin B in healthy participants (HPs).
Timeline
- Start
- 2026-03-22
- Primary completion
- 2026-09-30
- Completion
- 2026-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Polymyxin B | Peptide | 50 mg | Intravenous |
| Subject | Rifabutin | Small molecule | 300 mg | Intravenous |
Indications
No indication recorded.